Vasodilating beta-blockers in heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Carvedilol, a non-selective beta-adrenoceptor antagonist with vasodilating properties, is effective for hypertension and stable angina.
• Its efficacy in patients with manifest heart failure, particularly those with abnormal left ventricular (LV) function, requires further investigation.

Purpose of the Study:

• To explore the efficacy of carvedilol in patients with chronic stable angina and abnormal LV wall motion but without overt heart failure.
• To assess the hemodynamic and clinical responses to carvedilol in patients with chronic ischemic heart failure.

Main Methods:

• A preliminary single-blind, placebo-controlled study involved six patients with abnormal LV wall motion receiving escalating doses of carvedilol.
• A subsequent study assessed 17 patients with chronic ischemic heart failure using intravenous and oral carvedilol (50 mg b.i.d.) for 8 weeks.

Main Results:

• In the preliminary study, carvedilol improved LV wall motion in four of six patients, increasing mean ejection fraction from 40% to 48%.
• The second study showed improved hemodynamic variables in chronic ischemic heart failure patients, though two withdrew due to postural hypotension and two showed clinical deterioration.
• Beneficial effects are attributed to reduced afterload and inhibited neurohumeral activation, with findings supported by placebo-controlled, double-blind studies.

Conclusions:

• Carvedilol demonstrates potential benefits in improving cardiac function and hemodynamics in patients with heart failure and abnormal LV function.
• The drug's vasodilating and beta-blocking properties may contribute to its efficacy, but careful monitoring for side effects like postural hypotension is necessary.